Merck reported strong performance in key areas like JANUVIA and KEYTRUDA, exceeded expense reduction targets, and provided optimistic guidance for the full year. The robust product pipeline and strategic initiatives further bolster investor confidence. These factors are likely to positively influence the stock in the short term.

[1]